Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Fragile markets break earnings season hearts

This article was originally published in Scrip

Executive Summary

Last week was horrible. Dramatic falls in stock markets for any reason real or imagined will usually take a dent out of the valuations of even the most defensive of healthcare companies. That was happening last week until Friday when central bankers on both side of the Atlantic temporarily soothed nerves by suggesting that quantitative easing may not stop (or may start for those in the Eurozone), and interest rates won't rise, at least in the near future. If that wasn't enough, one branch of the US government has unilaterally started to invite inverting company CEOs down to the damp basements of Federal buildings to sit under strong lights until they are persuaded to call off their M&A transactions (scripintelligence.com, 16 October 2014). The only hope for investors was a set of good financial reports from the biggest companies in order to head off the flight away from risky assets.

You may also be interested in...



Stockwatch: The Post-Pandemic Dynamics Of Coronavirus Vaccines

Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.

Stockwatch: The Lexicon Of Biotech Survival

Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.

Stockwatch: Pandemic Cuts Deep Into Early Commercial Biotech

Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel